7c62dcca-2f51-462a-9bf7-5852d48469d9

https://www.fda.gov/news-events/2024-pda-fda-joint-regulatory-conference-09092024

Virtual

2024 PDA/ FDA Joint Regulatory Conference

9e2ca09e-42ad-49b7-b426-ec48812572a4

https://www.fda.gov/drugs/news-events-human-drugs/adept-9-public-workshop-enhancing-diversity-therapeutics-development-pediatric-patients-09062024

Public

ADEPT-9: Public Workshop on Enhancing Diversity in Therapeutics Development for Pediatric Patients

21f07dfb-6da0-4e7b-b09d-aa27fb7215b6

https://www.fda.gov/drugs/news-events-human-drugs/fda-nih-regulatory-dos-and-donts-tips-fda-09042024

Symposium

FDA | NIH : Regulatory Do’s and Don’ts: Tips from FDA

90485600-e500-4093-9a51-f7f17e96c360

https://www.fda.gov/drugs/news-events-human-drugs/2024-compounding-quality-center-excellence-annual-conference-08212024

Public

2024 Compounding Quality Center of Excellence Annual Conference

7c62dcca-2f51-462a-9bf7-5852d48469d9

https://www.fda.gov/news-events/2024-pda-fda-joint-regulatory-conference-09092024

Virtual

2024 PDA/ FDA Joint Regulatory Conference

9e2ca09e-42ad-49b7-b426-ec48812572a4

https://www.fda.gov/drugs/news-events-human-drugs/adept-9-public-workshop-enhancing-diversity-therapeutics-development-pediatric-patients-09062024

Public

ADEPT-9: Public Workshop on Enhancing Diversity in Therapeutics Development for Pediatric Patients

21f07dfb-6da0-4e7b-b09d-aa27fb7215b6

https://www.fda.gov/drugs/news-events-human-drugs/fda-nih-regulatory-dos-and-donts-tips-fda-09042024

Symposium

FDA | NIH : Regulatory Do’s and Don’ts: Tips from FDA

90485600-e500-4093-9a51-f7f17e96c360

https://www.fda.gov/drugs/news-events-human-drugs/2024-compounding-quality-center-excellence-annual-conference-08212024

Public

2024 Compounding Quality Center of Excellence Annual Conference

b67103eb-12bc-401e-ba66-602f5362e1ae

https://www.fda.gov/drugs/news-events-human-drugs/evaluating-negative-symptoms-schizophrenia-clinical-trials-08162024

Workshop

Evaluating the Negative Symptoms of Schizophrenia in Clinical Trials

a7939261-b1b8-42bb-b7ac-8a92d48631de

https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-august-2-2024-meeting-genetic-metabolic-diseases-advisory

Public

UPDATED PUBLIC PARTICIPATION INFORMATION: August 2, 2024: Meeting of the Genetic Metabolic Diseases Advisory Committee Meeting Announcement

fe799252-c050-457e-9799-472040e60625

https://www.fda.gov/drugs/news-events-human-drugs/environmental-monitoring-compounding-07302024

Virtual

Environmental Monitoring in Compounding

b300ec59-af99-492f-ad41-1ed00c7211a2

https://www.fda.gov/drugs/news-events-human-drugs/fdas-fifth-online-controlled-substances-summit-07252024

Workshop

FDA’s Fifth Online Controlled Substances Summit

a439dd27-fd42-4c85-a64c-6d105abe19ee

https://www.fda.gov/advisory-committees/updated-agenda-information-july-25-2024-meeting-oncologic-drugs-advisory-committee-meeting

Workshop

UPDATED AGENDA INFORMATION : July 25, 2024 Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

39e875ba-044a-49aa-94fc-699f1fb29483

https://www.fda.gov/drugs/news-events-human-drugs/dataset-json-pilot-report-and-next-steps-07252024

Conference

Dataset-JSON Pilot Report and Next Steps

eed285d2-9a4b-44ee-9e18-00125dd93adb

https://www.fda.gov/drugs/news-events-human-drugs/introduction-fdas-office-trade-and-global-partnerships-07232024

Conference

Introduction to FDA’s Office of Trade and Global Partnerships

a099166e-287f-4c8a-9f1a-b86ae415f136

https://www.fda.gov/drugs/news-events-human-drugs/public-workshop-best-practices-meeting-management-under-pdufa-vii-07222024

Conference

Public Workshop: Best Practices for Meeting Management Under PDUFA VII

fe78dbef-bc5f-41eb-b5fd-b038ddaa6c22

https://www.fda.gov/drugs/news-events-human-drugs/office-pharmaceutical-quality-opq-reorganization-07112024

Public

Office of Pharmaceutical Quality (OPQ) Reorganization

3d0d06c7-bf6c-446d-a87c-db71b68dfbc5

https://www.fda.gov/drugs/news-events-human-drugs/evaluating-immunosuppressive-effects-utero-exposure-drug-and-biologic-products-07112024

Virtual

Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products